

FIG. 1



FIG. 2



FIG. 3



FIG. 4



FIG. 5


FDCPmix proliferation inhibition by INPROL: direct effect *in vitro*
INPROL
% Inhibition
80
60
40
20
0
100ng
50ng
25ng
5ng
0.5ng
0.05ng
Dose of INPROL

FIG. 6


INPROL effects dynamic of CFU's proliferation inhibition
TSP
INPROL
CONTROL
Percent CFU's in S-phase
Days after the TSP Injection
100
90
80
70
60
50
40
30
20
10
0
0
1
2
3
4
5
6
7
8

FIG. 7

FIG. 8


INPROL injected *in vivo* protects mice from the lethal duble 5FU treatment
CONTROL
INPROL
Percent survival
100
90
80
70
60
50
40
30
20
10
0
0
5
10
15
20
25
30
Days after the second 5FU injection


Survival of lethally irradiated
mice after treatment with INPROL
Percent survival
100
80
60
40
20
0
5
10
15
20
25
30
Days
CONTROL
INPROL

FIG. 9


Cell regeneration in BMLTC - L1210 cultures after combined AraC plus Inprol treatment
Control
AraC
AraC + Inprol
Cell concentration (x 10e6/ml)
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0
2
4
6
8
Days of the first week after treatment

FIG. 10A


Cell regeneration in BMLTC - L1210 cultures after combined AraC plus Inprol treatment
Cell concentration (x 10e6/ml)
3
2
1
0
0
2
4
6
8
Control
AraC
AraC + Inprol
Days of the third week after treatment

FIG. 10B


30 days radioprot ction by th bone marrow cells
after preincubation with (B) or without (A) INPROL
110
100
90
80
70
60
50
40
30
20
Percent survival
A
B
0
5
10
15
20
25
30
Days after transplantation of the bone marrow

FIG. 11


Marrow repopulating ability of BDF1 mice cells after incubation with SCP1
200
100
0
Colony number
BM CONTROL
BM + SCI
0.02
0.04
0.06
0.08
0.10
0.12
Part of femur transplanted

FIG. 12


Pre-B progenitors number in Lymphoid Long Term Culture
after preincubation with or without INPROL
WEEK 1
WEEK 2
WEEK 3
Colonies/10e5 cells
140
120
100
80
60
40
20
0
CONTROL
+ SCPI

FIG. 13

FIG. 15A



Analysis: Channel A

Peak No.	Time	Type	Height(μY)	Area(μY-sec)	Area%
	3.126	N1	691	7578	0.041
	3.315	N2	1011	5150	0.027
1	49.618	N	8584	349227	1.893
2	51.298	N	1456	20274	0.109
3	52.673	N1	138069	2633395	14.278
4	53.148	N2	271587	14050458	76.181
5	54.935	N3	33016	1332820	7.226
6	67.595	N	3270	44507	0.241
TOTAL AREA				18443409	99.996


INPROL improves the repopulating ability
(LTC-IC number) of leukemic peripheral blood cells
HEALTHY DONOR
CML PATIENT
CML PATIENT + SCI
LTC-IC number (%)
120
100
80
60
40
20
0
0
10
20
30
40
50
60
Days in culture

FIG. 14



Analysis: Channel A

Peak No.	Time	Type	Height(μY)	Area(μY-sec)	Area%
1	4.383	N1	3945	95125	0.119
2	5.080	N2	28639	330889	0.413
3	5.216	N3	49084	531867	0.665
4	7.980	N1	399424	1110511	1.389
5	8.100	Err'	1203320	2882013	3.605
6	8.241	N3	443249	1506159	1.884
7	8.386	N4	481563	2185702	2.734
8	8.533	N5	412886	1826165	2.284
9	8.701	N6	321500	842122	1.053
10	8.745	N7	404661	1610380	2.014
11	8.995	N8	435765	2489721	3.114
12	9.316	N9	517790	4801831	6.007

FIG. 15B

FIG. 15C

```
 1   2   3   4   5   6   7   8   9  10  11  12  13  14  15  16  17  18  19  20
Val Leu Ser Pro Ala Asp Lys Thr Asn Val Lys Ala Ala Trp Gly Lys Val Gly Ala His
GTG CTG TCT CCT GCC GAC AAG ACC AAC GTC AAG GCC GCC TGG GGT AAG GTC GGC GCG CAC

 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40
Ala Gly Glu Tyr Gly Ala Glu Ala Leu Glu Arg Met Phe Leu Ser Phe Pro Thr Thr Lys
GCT GGC GAG TAT GGT GCG GAG GCC CTG GAG AGg ATG TTC CTG TCC TTC CCC ACC ACC AAG

 41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60
Thr Tyr Phe Pro His Phe Asp Leu Ser His Gly Ser Ala Gln Val Lys Gly His Gly Lys
ACC TAC TTC CCG CAC TTC GAC CTG AGC CAC GGC TCT GCC CAG GTT AAG GGC CAC GGC AAG

 61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80
Lys Val Ala Asp Ala Leu Thr Asn Ala Val Ala His Val Asp Asp Met Pro Asn Ala Leu
AAG GTG GCC GAC GCG CTG ACC AAC GCC GTG GCG CAC GTG GAC GAC ATG CCC AAC GCG CTG

 81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99 100
Ser Ala Leu Ser Asp Leu His Ala His Lys Leu Arg Val Asp Pro Val Asn Phe Lys Leu
TCC GCC CTG AGC GAC CTG CAC GCG CAC AAG CTT CGG GTG GAC CCG GTC AAC TTC AAG CTC

101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
Leu Ser His Cys Leu Leu Val Thr Leu Ala Ala His Leu Pro Ala Glu Phe Thr Pro Ala
CTA AGC CAC TGC CTG CTG GTG ACC CTG GCC GCG CAC CTC CCC GCC GAG TTC ACC CCT GCG

121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141
Val His Ala Ser Leu Asp Lys Phe Leu Ala Ser Val Ser Thr Val Leu Thr Ser Lys Tyr Arg
GTG CAC GCC TCC CTG GAC AAG TTC CTG GCT TCT GTG AGC ACC GTG CTG ACC TCC AAA TAC CGT
```

Fig. 16A

```
 1   2   3   4   5   6   7   8   9  10  11  12  13  14  15  16  17  18  19  20
Val His Leu Thr Pro Glu Glu Lys Ser Ala Val Thr Ala Leu Trp Gly Lys Val Asn Val
GTG CAC CTG ACT CCT GAG GAG AAG TCT GCC GTT ACT GCC CTG TGG GGC AAG GTG AAC GTG

 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40
Asp Glu Val Gly Gly Glu Ala Leu Gly Arg Leu Leu Val Val Tyr Pro Trp Thr Gln Arg
GAT GAA GTT GGT GGT GAG GCC CTG GGC AGg CTG CTG GTG GTC TAC CTT TGG ACC CAG AGG

 41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60
Phe Phe Glu Ser Phe Gly Asp Leu Ser Thr Pro Asp Ala Val Met Gly Asn Pro Lys Val
TTC TTT GAG TCC TTT GGG GAT CTG TCC ACT CCT GAT GCT GTt ATG GGC AAC CCT AAG GTG

 61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80
Lys Ala His Gly Lys Lys Val Leu Gly Ala Phe Ser Asp Gly Leu Ala His Leu Asp Asn
AAG GCT CAT GGC AAG AAA GTG CTC GGT GCC TTT AGT GAT GGC CTG GCT CAC CTG GAC AAC

 81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99 100
Leu Lys Gly Thr Phe Ala Thr Leu Ser Glu Leu His Cys Asp Lys Leu His Val Asp Pro
CTC AAG GGC ACC TTT GCC ACA CTG AGT GAG CTG CAC TGT GAC AAG CTG CAC GTG GAT CCT

101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
Glu Asn Phe Arg Leu Leu Gly Asn Val Leu Val Cys Val Leu Ala His His Phe Gly Lys
GAG AAC TTC AGG CTG CTG GGC AAC GTG CTG GTC TGT GTG CTG GCC CAT CAC TTT GGC AAA

121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140
Glu Phe Thr Pro Pro Val Gln Ala Ala Tyr Gln Lys Val Val Ala Gly Val Ala Asn Ala
GAA TTC ACC CCA CCA GTG CAG GCT GCC TAT CAG AAA GTG GTG GCT GGT GTG GCT AAT GCC

141 142 143 144 145 146
Leu Ala His Lys Tyr His
CTG GCC CAC AAG TAT CAC
```

Fig. 16B



Fig. 16C

Fig 17A



Analysis: Channel A

Peak No.	Time	Type	Height(μV)	Area(μV-sec)	Area%
1	48.200	N	1627	20438	1.515
2	52.076	N1	7425	116793	8.671
3	52.510	N2	32010	881490	65.367
4	53.660	N3	10066	330153	24.487
Total Area				1348874	99.990

Fig. 17B



Analysis: Channel A

Peak No.	Time	Type	Height(μV)	Area(μV-sec)	Area%
1	47.110	N1	1727	24840	0.204
2	47.723	N2	75067	1758939	14.321
3	49.153	N3	188795	6206410	51.114
4	52.250	N1	81476	3046748	25.092
5	53.115	N2	13195	202166	1.664
6	53.613	N3	19211	914954	7.535
	65.753	N	318	8066	0.066
Total Area				12142123	99.996



Fig. 18

Fig. 19A



Fig. 19B




Comparison of Inprol and Hemoglobin Chains in FDCPmix Assay
45000
35000
25000
15000
CPM
INPROL
Hb beta chain
Hb alpha chain
Control
100
50
25
12.5
6.75
3.37
1.7
doses (ng)

Fig. 20